pro1184
mAbexperimental
Clinical trial activity
5 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
5
Phase 3
3
Phase 4
0
Earliest trial started Dec 7, 2022 (NCT05579366)
Timeline
Indications
Studied for
- Breast Neoplasms · Phase 1/Phase 2
- Carcinoma, Non-Small-Cell Lung · Phase 1/Phase 2
- Endometrial Neoplasms · Phase 3
- Fallopian Tube Neoplasms · Phase 1/Phase 2
- Hamartoma · Phase 1/Phase 2
- Lung Neoplasms · Phase 1/Phase 2
- Mesothelioma · Phase 1/Phase 2
- Ovarian Neoplasms · Phase 3
- Triple Negative Breast Neoplasms · Phase 1/Phase 2
- Uterine Neoplasms · Phase 1/Phase 2
Mechanism of action
- Folate receptor alphaBINDING AGENT
FOLR1
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07288177 | Phase 2 | Jan 31, 2026 | Genmab |
| NCT07225270 | Phase 3 | Jan 15, 2026 | Genmab |
| NCT07166094 | Phase 3 | Nov 21, 2025 | Genmab |
| NCT06619236 | Phase 3 | Dec 15, 2024 | Genmab |
| NCT05579366 | Phase 1/Phase 2 (Phase 2) | Dec 7, 2022 | ProfoundBio US Co. |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Genmab | For profit | 4 | 4 | 2 | 2024 |
| ProfoundBio US Co. | For profit | 1 | 1 | 1 | 2022 |
2 organizations
Page 1 / 1